Table 2.
Cycloplegic retinoscopic refractive error at age 2.5 years in the Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity clinical trial1
| Spherical equivalent refractions, D | Intravitreal bevacizumab
|
Laser
|
||
|---|---|---|---|---|
| Without recurrence | With recurrence | Without recurrence | With recurrence | |
| Zone I (87 eyes)* | 50 eyes | 2 eyes | 26 eyes | 9 eyes |
| Mean (SD) | −1.36 (3.34) | −5.25 (4.6) | −7.34 (7.44) | −11.61 (7.42) |
| Median (range) | −0.50 (−8 to 6) | −5.25 (−8.5 to −2) | −4.69 (−24.88 to 2) | −10 (−22 to 0.75) |
| Zone II posterior (124 eyes)** | 56 eyes | 2 eyes | 58 eyes | 8 eyes |
| Mean (SD) | −0.63 (2.56) | 0.88 (0) | −5.2 (5.77) | −10.42 (4.58) |
| Median (range) | 0 (−13 to 2.5) | 0.88 (0.88−0.88) | −4 (−19 to 3.5) | −11.5 (−15 to −2.63) |
Notes:
For zone I, the mean (SD) spherical equivalent refractions for the intravitreal bevacizumab group were −1.51 (3.42) D (median [range], −0.56 [−8.56 to 6] D), and for the laser group were −8.44 (7.57) D (median [range], −8.00 [−24.88 to 2] D) (P<0.001);
for zone II posterior, the mean (SD) spherical equivalent refractions for the intravitreal bevacizumab group were −0.58 (2.53) D (median [range], 0 [−13 to 2.5] D), and for the laser group were −5.83 (5.87) D (median [range], −4.88 [−19 to 3.50] D) (P<0.001). Reproduced with permission from JAMA Ophthalmol. 2014;132(11):1327–1333. Copyright©2014 American Medical Association. All rights reserved.1
Abbreviation: SD, standard deviation.